Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism

  • Ascendis Pharma A/S ASND has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH Forward Trial evaluating TransCon PTH in adult subjects with hypoparathyroidism (HP).
  • Key Findings of the Preliminary OLE Results:
    • Fifty-eight subjects continue in the open-label extension beyond 58 weeks as of May 7.
    • Data showed established physiologic calcium metabolism based upon normalization of 24-hour urine calcium excretion and a downward trend toward mid-normal levels in bone markers without using therapeutic calcium and vitamin D supplementation.
    • No treatment-related serious or severe adverse events occurred, and no treatment-emergent adverse events led to discontinuation of the study drug.
  • In addition to PaTH Forward, Ascendis Pharma is conducting the PaTHway Phase 3 trial in North America and Europe, evaluating the safety, tolerability, and efficacy of TransCon PTH.
  • Topline results are expected by the end of this year.
  • TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) designed to restore PTH at physiologic levels 24 hours each day.
  • Price Action: ASND shares closed 2% lower at $130.07 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsHypoparathyroidism
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!